Investing in SomaLogic
Interested in potential investment opportunities?
SomaLogic Business News
Blood test beats traditional predictors of multiple disease risks
Proteins in our blood could in future help provide a comprehensive “Liquid Health Check,” assessing our health and predicting the likelihood that we will we will develop a range of diseases, according to research published today in Nature Medicine. The study, by an international team of researchers led by scientists at SomaLogic, the University of California, San Francisco and Cambridge University in the UK, shows that large-scale measurement of proteins in a single blood test can provide important information about a wide range of health factors and can help to predict multiple disease risks.
SomaLogic announces three new appointments to board of directors
SomaLogic, a privately held precision health information company, announced today that it has appointed Anne Margulies, Harvard University Vice President and Chief Information Officer, Franck J. Moison, former Vice Chairman of Colgate-Palmolive, and private investor Richard “Rick” Post to its board of directors.
SomaLogic significantly expands key strategic collaboration with Novartis
SomaLogic, Inc., announced today that it has entered into a new ten-year agreement with its long-time pharmaceutical partner, Novartis, to expand the application of SomaLogic’s leading proteomic technology across the company’s drug discovery and development efforts. The agreement includes plans to analyze at least 250,000 clinical samples from across the Novartis drug development portfolio.
Patrick Terry announced as first Chief Commercial Officer of SomaLogic
SomaLogic announced today that Patrick Terry has joined the company as its first Chief Commercial Officer (CCO). A serial entrepreneur, biomedical science enthusiast and patient advocate, Terry is uniquely qualified to lead the commercialization of SomaLogic’s growing portfolio of protein-based precision health information products.
SomaLogic launches its first SomaSignal™ tests in select medical practices
SomaLogic today launched its first seven SomaSignal™ tests, which are delivered simultaneously to provide actionable health information across a diverse set of human diseases and conditions. Each SomaSignal™ test is built on SomaLogic’s proprietary SomaScan® Platform, which measures thousands of human proteins in a single blood sample. The company expects that eventually there will be hundreds of different SomaSignal™ tests on the SomaScan® Platform.
SomaLogic’s clinical laboratory re-accredited by the College of American Pathologists
SomaLogic announced today that its United States clinical laboratory (CLIA laboratory) has been re-accredited by the College of American Pathologists (CAP). The successful renewal of CAP accreditation is based on the results of a recent on-site inspection designed to ensure the highest laboratory standards.
Agilent and SomaLogic sign agreement for supply of custom microarrays
Agilent Technologies, Inc. (NYSE: A) and SomaLogic, Inc. (a privately held biotechnology company) today announced a multi-year supply agreement whereby Agilent will supply customized high-fidelity oligo microarrays for use in the nucleic acid detection step within SomaLogic’s novel SOMAscan assay, a protein measurement platform with applications across basic and clinical research, diagnostics, and pharmaceutical discovery and development.
For all the latest SomaLogic news, please visit our News and Events page.